117 related articles for article (PubMed ID: 31959545)
1. Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
Bourillon L; Demontoy S; Lenglet A; Zampieri A; Fraisse J; Jarlier M; Boissière-Michot F; Perrochia H; Rathat G; Garambois V; Bonnefoy N; Michaud HA; Chardès T; Tosi D; Pèlegrin A; Azria D; Larbouret C; Bourgier C
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):1039-1051. PubMed ID: 31959545
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
4. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Huang S; Li C; Armstrong EA; Peet CR; Saker J; Amler LC; Sliwkowski MX; Harari PM
Cancer Res; 2013 Jan; 73(2):824-33. PubMed ID: 23172311
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
8. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
9. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
10. Imaging EGFR and HER3 through
McKnight BN; Kuda-Wedagedara ANW; Sevak KK; Abdel-Atti D; Wiesend WN; Ku A; Selvakumar D; Carlin SD; Lewis JS; Viola-Villegas NT
Sci Rep; 2018 Jun; 8(1):9043. PubMed ID: 29899472
[TBL] [Abstract][Full Text] [Related]
11. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
12. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G; Haber L; Crocker LM; Shia S; Shao L; Dowbenko D; Totpal K; Wong A; Lee CV; Stawicki S; Clark R; Fields C; Lewis Phillips GD; Prell RA; Danilenko DM; Franke Y; Stephan JP; Hwang J; Wu Y; Bostrom J; Sliwkowski MX; Fuh G; Eigenbrot C
Cancer Cell; 2011 Oct; 20(4):472-86. PubMed ID: 22014573
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
[TBL] [Abstract][Full Text] [Related]
14. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.
Ogden A; Bhattarai S; Sahoo B; Mongan NP; Alsaleem M; Green AR; Aleskandarany M; Ellis IO; Pattni S; Li XB; Moreno CS; Krishnamurti U; Janssen EA; Jonsdottir K; Rakha E; Rida P; Aneja R
Sci Rep; 2020 Feb; 10(1):3009. PubMed ID: 32080212
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.
de Almeida VH; de Melo AC; Meira DD; Pires AC; Nogueira-Rodrigues A; Pimenta-Inada HK; Alves FG; Moralez G; Thiago LS; Ferreira CG; Sternberg C
Braz J Med Biol Res; 2017 Nov; 51(1):e6822. PubMed ID: 29160417
[TBL] [Abstract][Full Text] [Related]
16. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
[TBL] [Abstract][Full Text] [Related]
17. Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells.
He G; Di X; Yan J; Zhu C; Sun X; Zhang S
Cancer Sci; 2018 Dec; 109(12):3774-3782. PubMed ID: 30259607
[TBL] [Abstract][Full Text] [Related]
18. P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma.
Cho NH; Kim YB; Park TK; Kim GE; Park K; Song KJ
Gynecol Oncol; 2003 Nov; 91(2):346-53. PubMed ID: 14599865
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
Gaffney DK; Haslam D; Tsodikov A; Hammond E; Seaman J; Holden J; Lee RJ; Zempolich K; Dodson M
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):922-8. PubMed ID: 12829126
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
